Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1

Giuseppe Morelli;  ; Roberto Firpi; Patrick Horne; Joy Peter; L Akushevich; Monica Vainorius; Shelley George; A De La Rosa; G Prabhakar Reddy; Taylor J Evers; Richard F Arrendale; Tara L Kieffer; V Garg; Michael W Fried; David R. Nelson

doi:10.17554/j.issn.2224-3992.2015.04.535

Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1

Journal of Gastroenterology and Hepatology Research ◽

10.17554/j.issn.2224-3992.2015.04.535 ◽

2015 ◽

Vol 4 (5) ◽

pp. 1599-1604 ◽

Cited By ~ 2

Author(s):

Giuseppe Morelli ◽

◽

Roberto Firpi ◽

Patrick Horne ◽

Joy Peter ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin

Journal of Viral Hepatitis ◽

10.1111/jvh.12485 ◽

2015 ◽

Vol 23 (3) ◽

pp. 227-231

Author(s):

G. R. Foster ◽

P. Ferenci ◽

T. Asselah ◽

P. Mantry ◽

J.-F. Dufour ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Peginterferon And Ribavirin

Download Full-text

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(19)30417-0 ◽

2020 ◽

Vol 5 (10) ◽

pp. 918-926 ◽

Cited By ~ 4

Author(s):

Eric Lawitz ◽

Charles S Landis ◽

Steven L Flamm ◽

Maurizio Bonacini ◽

Grisell Ortiz-Lasanta ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Genotype 1 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Multicentre Phase

Download Full-text

Simeprevir plus Sofosbuvir for Hepatitis C Virus Genotype 4 Infection: A Phase 3, Open-Label Study

Journal of Hepatology ◽

10.1016/s0168-8278(16)00193-8 ◽

2016 ◽

Vol 64 (2) ◽

pp. S220-S221 ◽

Cited By ~ 3

Author(s):

M. Buti ◽

J.L. Calleja ◽

X. Forns ◽

M. Diago ◽

E. Ortega ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Genotype ◽

Open Label ◽

Phase 3 ◽

Genotype 4 ◽

Open Label Study ◽

Label Study

Download Full-text

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

Clinical Infectious Diseases ◽

10.1093/cid/cix289 ◽

2017 ◽

Vol 65 (1) ◽

pp. 13-19 ◽

Cited By ~ 13

Author(s):

Jordan J Feld ◽

Alnoor Ramji ◽

Stephen D Shafran ◽

Bernard Willems ◽

Paul Marotta ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 3 ◽

Virus Genotype ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Treatment Naïve

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Cited By ~ 208

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Null Response

Download Full-text

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

Gastroenterology ◽

10.1053/j.gastro.2015.07.001 ◽

2015 ◽

Vol 149 (4) ◽

pp. 971-980.e1 ◽

Cited By ~ 59

Author(s):

Eric Lawitz ◽

Mihály Makara ◽

Ulus Salih Akarca ◽

Paul J. Thuluvath ◽

Liliana Lucia Preotescu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Efficacy And Safety ◽

Hepatitis C Virus Infection ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Chronic Hepatitis C Virus

Download Full-text

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61793-1 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1087-1097 ◽

Cited By ~ 202

Author(s):

Mark Sulkowski ◽

Christophe Hezode ◽

Jan Gerstoft ◽

John M Vierling ◽

Josep Mallolas ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725223929.793501441 ◽

2014 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Pilot Study ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Chronic Hepatitis C Virus

Download Full-text

Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(17)30003-1 ◽

2017 ◽

Vol 2 (5) ◽

pp. 347-353 ◽

Cited By ~ 45

Author(s):

Jürgen K Rockstroh ◽

Sanjay Bhagani ◽

Robert H Hyland ◽

Chohee Yun ◽

Hadas Dvory-Sobol ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Acute Hepatitis ◽

Acute Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Hiv Coinfection

Download Full-text

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(17)30496-6 ◽

2017 ◽

Vol 17 (10) ◽

pp. 1062-1068 ◽

Cited By ~ 178

Author(s):

Xavier Forns ◽

Samuel S Lee ◽

Joaquin Valdes ◽

Sabela Lens ◽

Reem Ghalib ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Compensated Cirrhosis ◽

Chronic Hepatitis C Virus

Download Full-text